ArteraAI
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
108 1st St, Los Altos, California, 94022...Phone Number
(855) 278-3724Website
www.artera.aiRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About ArteraAI
ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer. Robust clinical data provides better resultsExplore more
ArteraAI Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ArteraAI your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ArteraAI
ArteraAI, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ArteraAI has new funding data
Website visits: Recent activity has been detected on your website
Check out if ArteraAI is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ArteraAI recently announced quarterly report
Product Launch: Get notified when ArteraAI launches new products
Check if ArteraAI has recently received funding, and reach out quickly before it becomes old news!
Click to see if ArteraAI had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to ArteraAI
Compare insights from companies similar to ArteraAI, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ArteraAI is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ArteraAI is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ArteraAI.
ArteraAI financials insights
Gather financial insights about ArteraAI, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$90M
2024
Other Financing Round
$20M
ArteraAI Tech Stack
A closer look at the technologies used by ArteraAI
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Product Launch, Medical Research
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Open Position
ArteraAI News & Media
U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer. Breakthrough Device Designation may expedite the FDA authorization process for the ArteraAIArtera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer. Additionally, the study will monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera's commitment to advancing persoArtera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States. This milestone comes on the heels of Artera’s recent announcement thaThe ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated its award-winning ArteraAI Prostate Test with new insights to help higher-risk patients optimize treatment decisions. Artera recently presented its validation data at the 2025 ASCO Annual Meeting, demonstrating the test’s ability to identify high-risk, non-metastatic prostate cancer patients most likely to benefit from the addition of abira
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ArteraAI
Sign Up For FreeTo access detailed company insights
ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer. Robust clinical data provides better results... Read More
